Home / Intelligence / Webinars / How to Develop Strong Evidence to Enable Optimal Access Recording
Available On Demand

Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.
- But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
- What are the ‘nuts and bolts’ of designing and conducting such studies?
- How do you distill down to the key value messages from a complex data set to be most impactful to clinical and payer audiences?
Learn how Burden of Illness studies are conducted and how this study type could support your disease areas! The Trinity team will highlight the importance of evidence generation through the lens of a scientific Burden of Illness study that we recently conducted with a global pharma company. Beyond the scientific implications of studies of this kind, we will delve into the real-world applications of this evidence from a market access perspective.
Please complete the form to watch our Trinity Webinar: How to Develop Strong Evidence to Enable Optimal Access.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now